Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A proposed statistical framework for the management of subgroup analyses for large clinical trials.

Luo X, Chen P, Wu AC, Pan G, Li M, Chen G, Dong Q, Cline GA, Dornseif BE, Jin Z.

Contemp Clin Trials. 2015 Nov;45(Pt B):239-243. doi: 10.1016/j.cct.2015.09.013. Epub 2015 Sep 24.

PMID:
26388115
2.

The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.

Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A, Gershon MD.

Gastroenterology. 2011 Aug;141(2):507-16. doi: 10.1053/j.gastro.2011.05.005. Epub 2011 May 18.

3.

Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.

Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO 3rd.

Osteoarthritis Cartilage. 2008 Jun;16(6):660-6. Epub 2007 Nov 13.

4.

Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.

Racewicz AJ, Schofield PJ, Cahall DL, Cline GA, Burgio DE.

Curr Med Res Opin. 2007 Dec;23(12):3079-89.

PMID:
17971285
6.

Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Abram F, Choquette D, Haraoui B, Beary JF, Cline GA, Meyer JM, Pelletier JP.

Ann Rheum Dis. 2008 May;67(5):683-8. Epub 2007 Aug 29.

PMID:
17728333
7.

Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study.

Pelletier JP, Raynauld JP, Berthiaume MJ, Abram F, Choquette D, Haraoui B, Beary JF, Cline GA, Meyer JM, Martel-Pelletier J.

Arthritis Res Ther. 2007;9(4):R74.

8.

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.

Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF.

Arthritis Rheum. 2006 Nov;54(11):3494-507.

9.

Comparison of fixed flexion, fluoroscopic semi-flexed and MTP radiographic methods for obtaining the minimum medial joint space width of the knee in longitudinal osteoarthritis trials.

Cline GA, Meyer JM, Stevens R, Buckland-Wright C, Peterfy C, Beary JF.

Osteoarthritis Cartilage. 2006;14 Suppl A:A32-6. Epub 2006 May 8.

10.

Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, Tannenbaum H, Meyer JM, Beary JF, Cline GA, Pelletier JP.

Arthritis Res Ther. 2006;8(1):R21. Epub 2005 Dec 30.

11.

Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.

Adami S, Pavelka K, Cline GA, Hosterman MA, Barton IP, Cohen SB, Bensen WG.

Mayo Clin Proc. 2005 Oct;80(10):1278-85.

PMID:
16212139
12.

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].

Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM.

Arthritis Res Ther. 2005;7(3):R625-33. Epub 2005 Mar 24.

13.

Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging.

Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beaudoin G, Bloch DA, Choquette D, Haraoui B, Altman RD, Hochberg M, Meyer JM, Cline GA, Pelletier JP.

Ann Rheum Dis. 2005 Apr;64(4):556-63. Epub 2004 Sep 16.

14.

Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Labonté F, Beaudoin G, de Guise JA, Bloch DA, Choquette D, Haraoui B, Altman RD, Hochberg MC, Meyer JM, Cline GA, Pelletier JP.

Arthritis Rheum. 2004 Feb;50(2):476-87.

15.

X-ray technologists' reproducibility from automated measurements of the medial tibiofemoral joint space width in knee osteoarthritis for a multicenter, multinational clinical trial.

Buckland-Wright JC, Bird CF, Ritter-Hrncirik CA, Cline GA, Tonkin C, Hangartner TN, Ward RJ, Meyer JM, Meredith MP.

J Rheumatol. 2003 Feb;30(2):329-38.

PMID:
12563691

Supplemental Content

Loading ...
Support Center